Non-invasive prenatal testing: a revolutionary journey in prenatal testing.

Autor:	Abedalthagafi M; Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA, United States.; King Salman Center for Disability Research, Riyadh, Saudi Arabia., Bawazeer S; Department of Medical Genetics, Children's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia., Fawaz RI; Baylor Genetics, Houston, TX, United States., Heritage AM; Baylor Genetics, Houston, TX, United States., Alajaji NM; Department of Maternal Fetal Medicine, Women's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia., Faqeih E; Department of Medical Genetics, Children's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2023 Nov 09; Vol. 10, pp. 1265090. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
DOI:	10.3389/fmed.2023.1265090
Abstrakt:	Non-invasive prenatal testing (NIPT) is a pioneering technique that has consistently advanced the field of prenatal testing to detect genetic abnormalities and conditions with the aim of decreasing the incidence and prevalence of inherited conditions. NIPT remains a method of choice for common autosomal aneuploidies, mostly trisomy 21, and several monogenic disorders. The advancements in gene sequencing techniques have expanded the panel of conditions where NIPT could be offered. However, basic research on the impact of several genetic conditions lags behind the methods of detection of these sequence aberrations, and the impact of the expansion of NIPT should be carefully considered based on its utility. With interest from commercial diagnostics and a lack of regulatory oversight, there remains a need for careful validation of the predictive values of different tests offered. NIPT comes with many challenges, including ethical and economic issues. The scientific evidence, technical feasibility, and clinical benefit of NIPT need to be carefully investigated before new tests and developments are translated into clinical practice. Moreover, the implementation of panel expansion of NIPT should accompany expert genetic counseling pre- and post-testing. Competing Interests: MA is a founder of Shomool, which specializes in NIPT for ARD. RF and AM are employed by Baylor Genetics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Abedalthagafi, Bawazeer, Fawaz, Heritage, Alajaji and Faqeih.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu